NASDAQ:VYGR

Voyager Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy VYGR

*Your capital is at risk

$3.60

+0.0100 (+0.279%)

At Close: Jun 03, 2026

Voyager Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 20.41. In total, the insiders bought 4.62M and sold 313.57K VYGR shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	20.41
● Buy	4.62M shares
● Sell	313.57K shares
59% Buy Activity Strong Positive Correlation
Sell Signal Low Confidence Feb 24, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 20.41. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Apr 02, 2025 Sell	Common Stock S-Sale	Sandrock Alfred President And CEO	CEO / President	10 885 Value: $37.3K
Apr 02, 2025 Sell	Common Stock S-Sale	Sandrock Alfred President And CEO	CEO / President	10 885 Value: $37.3K
Apr 02, 2025 Sell	Common Stock S-Sale	Ferguson Toby Chief Medical Officer	Officer	10 086 Value: $34.6K
Feb 21, 2025 Buy	Common Stock A-Award	Carter Todd Alfred Chief Scientific Officer	Officer	46 000 Value: $194.1K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Carter Todd Alfred Chief Scientific Officer	Officer	92 000 Value: $388.2K
Feb 21, 2025 Buy	Common Stock A-Award	Sandrock Alfred President And CEO	CEO / President	145 000 Value: $611.9K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Sandrock Alfred President And CEO	CEO / President	290 000 Value: $1.22M
Feb 21, 2025 Buy	Common Stock A-Award	Swartz Robin COO & Cbo	C-Suite Officer	71 250 Value: $300.7K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Swartz Robin COO & Cbo	C-Suite Officer	142 500 Value: $601.4K
Feb 21, 2025 Buy	Common Stock A-Award	Fahey Sandell Jacquelyn Chief Legal Officer	Officer	41 500 Value: $175.1K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Fahey Sandell Jacquelyn Chief Legal Officer	Officer	83 000 Value: $350.3K
Feb 21, 2025 Buy	Common Stock A-Award	Ferguson Toby Chief Medical Officer	Officer	63 000 Value: $265.9K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferguson Toby Chief Medical Officer	Officer	126 000 Value: $531.7K
Feb 21, 2025 Buy	Common Stock A-Award	Jorgensen Nathan D. Chief Financial Officer	C-Suite Officer	51 500 Value: $217.3K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Jorgensen Nathan D. Chief Financial Officer	C-Suite Officer	103 000 Value: $434.7K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Jorgensen Nathan D. Chief Financial Officer	C-Suite Officer	103 000 Value: $434.7K
Feb 21, 2025 Buy	Common Stock A-Award	Jorgensen Nathan D. Chief Financial Officer	C-Suite Officer	51 500 Value: $217.3K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Ferguson Toby Chief Medical Officer	Officer	126 000 Value: $531.7K
Feb 21, 2025 Buy	Common Stock A-Award	Ferguson Toby Chief Medical Officer	Officer	63 000 Value: $265.9K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Fahey Sandell Jacquelyn Chief Legal Officer	Officer	83 000 Value: $350.3K
Feb 21, 2025 Buy	Common Stock A-Award	Fahey Sandell Jacquelyn Chief Legal Officer	Officer	41 500 Value: $175.1K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Swartz Robin COO & Cbo	C-Suite Officer	142 500 Value: $601.4K
Feb 21, 2025 Buy	Common Stock A-Award	Swartz Robin COO & Cbo	C-Suite Officer	71 250 Value: $300.7K
Feb 21, 2025 Buy	Stock Option (Right to Buy) A-Award	Sandrock Alfred President And CEO	CEO / President	290 000 Value: $1.22M
Feb 21, 2025 Buy	Common Stock A-Award	Sandrock Alfred President And CEO	CEO / President	145 000 Value: $611.9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VOYAGER THERAPEUTICS

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau...

Read Full Profile Here